Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The 'cancer cachectic factor'.

Michael J Tisdale1

  • 1Pharmaceutical Sciences Research Institute, Aston University, Birmingham B4 7ET, United Kingdom. M.J.Tisdale@aston.ac.uk

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|February 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression.

Scientific reports·2020
Same author

Ken Fearon.

Cell metabolism·2016
Same author

In vitro assessment of the combined effect of eicosapentaenoic acid, green tea extract and curcumin C3 on protein loss in C2C12 myotubes.

In vitro cellular & developmental biology. Animal·2016
Same author

Comparison of the anticatabolic effects of leucine and Ca-β-hydroxy-β-methylbutyrate in experimental models of cancer cachexia.

Nutrition (Burbank, Los Angeles County, Calif.)·2014
Same author

Attenuation of muscle wasting in murine C2C 12 myotubes by epigallocatechin-3-gallate.

Journal of cachexia, sarcopenia and muscle·2014
Same author

Role of β-adrenergic receptors in the oral activity of zinc-α2-glycoprotein (ZAG).

Endocrinology·2012

Cancer cachexia involves a proteolysis-inducing factor (PIF) that causes muscle wasting. Eicosapentaenoic acid (EPA) can counteract PIF, stabilizing weight and increasing lean mass in cancer patients.

Area of Science:

  • Biochemistry
  • Oncology
  • Molecular Biology

Background:

  • Cancer cachexia is characterized by significant weight loss and muscle wasting.
  • Tumor-derived factors contribute to the catabolic state in cancer patients.
  • The ATP-ubiquitin-dependent proteolytic pathway plays a crucial role in muscle protein degradation.

Purpose of the Study:

  • To identify and characterize catabolic factors produced by tumors in cancer cachexia.
  • To elucidate the mechanism of tissue catabolism induced by these factors.
  • To explore therapeutic strategies targeting cancer cachexia.

Main Methods:

  • Isolation of cachectic factors using standard biochemical methods.
  • In vitro and in vivo evaluation of tissue catabolism mechanisms.

Related Experiment Videos

  • Analysis of mRNA levels for ubiquitin and proteasome subunits.
  • Administration of eicosapentaenoic acid (EPA) in vitro and in vivo.

    • Main Results:

    • A 24-kDa sulphated glycoprotein, proteolysis-inducing factor (PIF), was isolated from cachexia-inducing tumors.
    • PIF administration to mice caused rapid weight loss, primarily from skeletal muscle, and increased ubiquitin-proteasome pathway components.
    • PIF was detected in various carcinomas associated with significant weight loss.
    • Eicosapentaenoic acid (EPA) attenuated PIF's catabolic effects in vitro and in vivo.
    • Oral EPA stabilized body weight and increased lean body mass in advanced pancreatic cancer patients, especially when combined with nutritional support.

    Conclusions:

    • Proteolysis-inducing factor (PIF) drives muscle wasting in cancer cachexia via the ubiquitin-proteasome pathway, independent of nutrient intake.
    • Eicosapentaenoic acid (EPA) effectively counteracts PIF-induced muscle catabolism.
    • EPA represents a promising therapeutic agent for managing cancer cachexia and improving body composition in cancer patients.